Skip to main content
. 2020 May 18;123(3):426–437. doi: 10.1038/s41416-020-0884-9

Fig. 1. miR-622 is downregulated in plasma and in tissues of breast cancer patients.

Fig. 1

Relative miR-622 expression level was analysed by q-RT-PCR in the plasma of healthy controls (n = 17) compared to the plasma of all breast cancer patients (n = 39) (a) or of breast cancer specific subtypes (b). Correlations between plasma miR-622 expression levels and tumour grade (c), and Ki67 expression (low <30%; high ≥30%) (d) in breast cancer patients. e Relative expression level of miR-622 in breast tumour formalin-fixed paraffin-embedded tissues compared to respective adjacent non-tumour tissues (n = 20). Each experiment was performed twice in triplicate and data are expressed as median with interquartile range. f Kaplan–Meier survival plot of miR-622 in the triple-negative breast cancer (TNBC), in oestrogen receptor (ER)-negative, epidermal growth factor receptor 2 (HER2 pos) and in luminal B samples using the TCGA dataset. Hazard ratio (HR) values for miR-622 and overall survival (OS Probability) and log-rank p values are reported. *p < 0.05; **p < 0.01.